| pubmed-article:16724093 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16724093 | lifeskim:mentions | umls-concept:C0242957 | lld:lifeskim |
| pubmed-article:16724093 | lifeskim:mentions | umls-concept:C0012854 | lld:lifeskim |
| pubmed-article:16724093 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:16724093 | lifeskim:mentions | umls-concept:C0301872 | lld:lifeskim |
| pubmed-article:16724093 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:16724093 | lifeskim:mentions | umls-concept:C1511767 | lld:lifeskim |
| pubmed-article:16724093 | pubmed:issue | 19 | lld:pubmed |
| pubmed-article:16724093 | pubmed:dateCreated | 2006-9-19 | lld:pubmed |
| pubmed-article:16724093 | pubmed:abstractText | HER-2/neu is a candidate for developing breast cancer-targeted immunotherapeutics. Although DNA-based and HER-2/neu transgene-modified dendritic cell (DC)-based vaccines are potent at eliciting HER-2/neu-specific antitumor immunity, there has been no side-by-side study comparing them directly. The present study utilizes an in vivo murine tumor model expressing HER-2/neu antigen to compare the efficacy between adenovirus (AdVneu)-transfected dendritic cells (DC(neu)) and plasmid DNA (pcDNAneu) vaccine. Our data showed that DC(neu) upregulated the expression of immunologically important molecules and inflammatory cytokines and partially converted regulatory T (Tr)-cell suppression through interleukin-6 (IL-6) secretion. Vaccination of DC(neu) induced stronger HER-2/neu-specific humoral and cellular immune responses than DNA vaccination, which downregulated HER-2/neu expression and lysed HER-2/neu-positive tumor cells in vitro, respectively. In two HER-2/neu-expressing tumor models, DC(neu) completely protected mice from tumor cell challenge compared to partial or no protection observed in DNA-immunized mice. In addition, DC(neu) significantly delayed breast cancer development in transgenic mice in comparison to DNA vaccine (P<0.05). Taken together, we have demonstrated that HER-2/neu-gene-modified DC vaccine is more potent than DNA vaccine in both protective and preventive animal tumor models. Therefore, DCs genetically engineered to express tumor antigens such as HER-2/neu represent a new direction in DC vaccine of breast cancer. | lld:pubmed |
| pubmed-article:16724093 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16724093 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16724093 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16724093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16724093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16724093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16724093 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16724093 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:16724093 | pubmed:issn | 0969-7128 | lld:pubmed |
| pubmed-article:16724093 | pubmed:author | pubmed-author:GuyRR | lld:pubmed |
| pubmed-article:16724093 | pubmed:author | pubmed-author:ChanTT | lld:pubmed |
| pubmed-article:16724093 | pubmed:author | pubmed-author:SamiAA | lld:pubmed |
| pubmed-article:16724093 | pubmed:author | pubmed-author:XiangJJ | lld:pubmed |
| pubmed-article:16724093 | pubmed:author | pubmed-author:El-GayedAA | lld:pubmed |
| pubmed-article:16724093 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16724093 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:16724093 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16724093 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16724093 | pubmed:pagination | 1391-402 | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:meshHeading | pubmed-meshheading:16724093... | lld:pubmed |
| pubmed-article:16724093 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16724093 | pubmed:articleTitle | HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. | lld:pubmed |
| pubmed-article:16724093 | pubmed:affiliation | Cancer Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4. | lld:pubmed |
| pubmed-article:16724093 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16724093 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16724093 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16724093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16724093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16724093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16724093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16724093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16724093 | lld:pubmed |
